Personalized Cell TherapyPersonalized Cell TherapyC Y T O R IC Y T O R I
A TRUSTED LEADER IN CELL THERAPY
NASDAQ: CYTX
Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
...
Personalized Cell TherapyPersonalized Cell Therapy
Improve the quality & length of life
through innovative CELL THERAPY pr...
World’s Safest Therapeutic Cells that HealWorld’s Safest Therapeutic Cells that Heal
4
T R U S T E D L E A D E R I N C E L...
CYTORI: A Biotech Company
Near-Term Biotech Value Drivers
* US Clinical Trial Data
Q2, ’14 - ATHENA
* US Gov’t Contract Ex...
1) Advance US Clinical Pipeline
2) Expand Global Clinical Development Pipeline via
commercial business with positive contr...
• US Heart Failure Indication
– ATHENA (enrollment / Data)
– ATHENA II
– Type C Meeting with FDA
• BARDA Complete Phase I ...
ATHENA TrialATHENA Trial
• Added 3 new sites (initiating in September) for a total of 8 sites
• Amendment approved by FDA ...
Commercial Business
Focused on Research Market Sales
• Investigator Initiated Studies
• Indication specific global patient...
Commercial: Focused on Revenue Generating
Clinical Development Pipeline
GLOBAL INVESTIGATOR INITIATED CLINICAL STUDIES
Lat...
• $4.7 MM in funding
• Preclinical model
• Next-Gen Celution®
development
• Up to 2 years
ProofProof--ofof--
ConceptConcep...
Strengthen Financial PositionStrengthen Financial Position
 Debt refinance compete:
 $8 million additional cash into the...
Dominant Intellectual Property Estate
62+ Issued Patents; 75+ Pending
DEVICES
CURRENT
DEVICES
NEXT GENERATION
COSMETIC & R...
Key MilestonesKey Milestones
 Australia, New Zealand Approvals
• Complete enrollment in the ATHENA trial
• Report six mon...
Key MilestonesKey Milestones
• Expand clinical development pipeline via
investigator initiated studies
• Additional Japan ...
Personalized Cell TherapyPersonalized Cell TherapyC Y T O R IC Y T O R I
T H A N K Y O U !
Upcoming SlideShare
Loading in …5
×

Annual Shareholder Meeting 2013

693 views

Published on

CEO Chris Calhoun presents a company overview at the Company's annual shareholder meeting on August 28, 2013

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
693
On SlideShare
0
From Embeds
0
Number of Embeds
319
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Annual Shareholder Meeting 2013

  1. 1. Personalized Cell TherapyPersonalized Cell TherapyC Y T O R IC Y T O R I A TRUSTED LEADER IN CELL THERAPY NASDAQ: CYTX
  2. 2. Safe Harbor Statement This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward- looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation involve known and unknown risks that relate to Cytori’s future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission for a more detailed description of these risks. The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Cytori’s expectations. This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward- looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation involve known and unknown risks that relate to Cytori’s future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission for a more detailed description of these risks. The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Cytori’s expectations. 2
  3. 3. Personalized Cell TherapyPersonalized Cell Therapy Improve the quality & length of life through innovative CELL THERAPY products Improve the quality & length of life through innovative CELL THERAPY products C E L L T H E R A P Y
  4. 4. World’s Safest Therapeutic Cells that HealWorld’s Safest Therapeutic Cells that Heal 4 T R U S T E D L E A D E R I N C E L L T H E R A P Y
  5. 5. CYTORI: A Biotech Company Near-Term Biotech Value Drivers * US Clinical Trial Data Q2, ’14 - ATHENA * US Gov’t Contract Expansion Q1, ’14 - BARDA * Strategic Partnership Adipose-derived stem & regenerative cells (ADRCs) 5 Near-Term Biotech Value Drivers * US Clinical Trial Data Q2, ’14 - ATHENA * US Gov’t Contract Expansion Q1, ’14 - BARDA * Strategic Partnership
  6. 6. 1) Advance US Clinical Pipeline 2) Expand Global Clinical Development Pipeline via commercial business with positive contribution margin 3) Strengthen Financial Position Corporate ObjectivesCorporate Objectives 1) Advance US Clinical Pipeline 2) Expand Global Clinical Development Pipeline via commercial business with positive contribution margin 3) Strengthen Financial Position
  7. 7. • US Heart Failure Indication – ATHENA (enrollment / Data) – ATHENA II – Type C Meeting with FDA • BARDA Complete Phase I – Initiate Phase II of contract • Commercial efforts focused on Investigator Initiated Studies and generating growth & positive contribution margin in each region • Sustainable Organization – Capital Plan – Achieve Budget Goals (revenue, margins, costs) Vital PrioritiesVital Priorities • US Heart Failure Indication – ATHENA (enrollment / Data) – ATHENA II – Type C Meeting with FDA • BARDA Complete Phase I – Initiate Phase II of contract • Commercial efforts focused on Investigator Initiated Studies and generating growth & positive contribution margin in each region • Sustainable Organization – Capital Plan – Achieve Budget Goals (revenue, margins, costs)
  8. 8. ATHENA TrialATHENA Trial • Added 3 new sites (initiating in September) for a total of 8 sites • Amendment approved by FDA and all IRBs • Amendment to ATHENA (submitted to FDA) to change in inclusion criteria related to nuclear medicine scanning as recommended by SAB • New enrollment material to support sites & micro site is online: www.theathenatrial.com • Aggressive site contact program • New clinical leadership & entire clinical team • IDE approved for ATHENA II with key change in inclusion criteria related to nuclear medicine scanning as recommended by our SAB • Added 3 new sites (initiating in September) for a total of 8 sites • Amendment approved by FDA and all IRBs • Amendment to ATHENA (submitted to FDA) to change in inclusion criteria related to nuclear medicine scanning as recommended by SAB • New enrollment material to support sites & micro site is online: www.theathenatrial.com • Aggressive site contact program • New clinical leadership & entire clinical team • IDE approved for ATHENA II with key change in inclusion criteria related to nuclear medicine scanning as recommended by our SAB 8
  9. 9. Commercial Business Focused on Research Market Sales • Investigator Initiated Studies • Indication specific global patient Registries • Targeting KOLs for specific indications • Expand ongoing IIS and Pilot work to new centers • Expanding into new markets, and expanding exiting claims Increasing installed base of systems – est > 200 in the field Limited consumable sales due to current market dominated by research customers Registry use and new therapeutic targeted customers will provide more repeat consumable sales – including our multiple CV sales Changing Regulatory Landscape in Japan could open first Medical markets with Full Market Access Positive contribution margin – profitable revenue by region 9 Focused on Research Market Sales • Investigator Initiated Studies • Indication specific global patient Registries • Targeting KOLs for specific indications • Expand ongoing IIS and Pilot work to new centers • Expanding into new markets, and expanding exiting claims Increasing installed base of systems – est > 200 in the field Limited consumable sales due to current market dominated by research customers Registry use and new therapeutic targeted customers will provide more repeat consumable sales – including our multiple CV sales Changing Regulatory Landscape in Japan could open first Medical markets with Full Market Access Positive contribution margin – profitable revenue by region
  10. 10. Commercial: Focused on Revenue Generating Clinical Development Pipeline GLOBAL INVESTIGATOR INITIATED CLINICAL STUDIES Late Stage Active Complete/Published Total Wound Healing 7 4 8 19 Sports / Ortho 3 7 0 10 Soft Tissue 2 7 4 13 Cardiovascular 8 1 0 9 Other 1 2 1 4 Total 21 21 13 55 10 Late Stage Active Complete/Published Total Wound Healing 7 4 8 19 Sports / Ortho 3 7 0 10 Soft Tissue 2 7 4 13 Cardiovascular 8 1 0 9 Other 1 2 1 4 Total 21 21 13 55 8 Approved IIS in Japan plus 6 current applications under review
  11. 11. • $4.7 MM in funding • Preclinical model • Next-Gen Celution® development • Up to 2 years ProofProof--ofof-- ConceptConcept • Up to $56 MM • Development including clinical • Govt. has procurement ability Options 1 & 2Options 1 & 2 • Up to $45 MM • Pivotal trial • FDA submission Option 3Option 3 BARDA: $106 M Contract  Processing Next Gen Celution produces comparable output to Celution 800  Availability ADRCs can be extracted from patients with thermal burn injury  Function ADRCs from an irradiated animal improve healing of concomitant thermal burn Proof-of-Concept Success unlocks Options 1 & 2 – up to $ 56 Million targeted for Q1, ‘14
  12. 12. Strengthen Financial PositionStrengthen Financial Position  Debt refinance compete:  $8 million additional cash into the company  defer principal payments 12+ months  PureGraft Asset divestiture • Cash, A/R at end of Q2 (pro-forma) $ 21.5 million – Cash includes $5 M from PG asset divestiture • 2 Key US Milestones with in 12 months – BARDA – ATHENA – US Phase II data • Capital Plan – Strategic partnerships – Equity  Debt refinance compete:  $8 million additional cash into the company  defer principal payments 12+ months  PureGraft Asset divestiture • Cash, A/R at end of Q2 (pro-forma) $ 21.5 million – Cash includes $5 M from PG asset divestiture • 2 Key US Milestones with in 12 months – BARDA – ATHENA – US Phase II data • Capital Plan – Strategic partnerships – Equity 12
  13. 13. Dominant Intellectual Property Estate 62+ Issued Patents; 75+ Pending DEVICES CURRENT DEVICES NEXT GENERATION COSMETIC & RECONSTRUCTIVE SURGERY CARDIOVASCULAR THERAPIES PIPELINE THERAPIES US: (6) CELUTION DEVICE (‘484) CELUTION DEVICE PLUS ADDITIVES (‘420) STEMSOURCE DEVICE (‘115) CELUTION DEVICE PLUS SENSORS FOR CLINICALLY SAFE OUTPUT (‘670) BEDSIDE COMPREHENSIVE DEVICE (‘059) CELUTION DEVICE CD31 POSITIVE CELLS (‘276) JAPAN: (2) CELUTION DEVICE (‘952) CELUTION FOR CLINICALLY SAFE OUTPUT (‘556) KOREA: (3) CELUTION DEVICE (‘995) STEMSOURCE DEVICE (‘812) CELUTION DEVICE (‘139) INDIA: (1) CELUTION DEVICE (‘706) AUSTRALIA: (2) CELUTION DEVICE (‘135) STEMSOURCE DEVICE (‘901) CHINA: (1) CELUTION DEVICE (‘689) US: (1) CELUTION & FUTURE GENERATIONS (‘075) CHINA: (1) CELUTION & FUTURE GENERATIONS (‘241) INDIA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘529) AUSTRALIA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘937) SINGAPORE: (1) CELUTION & FUTURE GENERATIONS (‘683) ISRAEL: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘800) MEXICO: (1) CELUTION & FUTURE GENERATIONS (‘348) KOREA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘305) US: (6) CELUTION FOR MIXING ADRCS PLUS FAT (‘488) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS (‘684) ADRCS PLUS FAT PLUS ADDITIVES (‘795) ADRCS PLUS FAT (‘672) ADRCS PLUS FAT COMPOSITION (‘121) CURRENT CELUTION DEVICE + FAT (‘947) JAPAN: (1) CELUTION AND NEXT GEN DEVICES FOR MIXING ADRCS PLUS FAT (‘041) KOREA: (3) ADRCS PLUS FAT (‘454) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS (‘508) ADRCS PLUS FAT METHOD (‘666) EUROPE: (2) ADRCS FOR CARDIAC (‘382) OPPOSED DEVICE FOR RESTORING BLOOD FLOW (‘575) OPPOSED AUSTRALIA: (1) ADRCS FOR CARDIAC (‘858) SINGAPORE: (1) ADRCS FOR RESTORING BLOOD FLOW(‘309) CHINA: (1) ADRCS FOR RESTORING BLOOD FLOW (‘104) HONG KONG: (1) ADRCS FOR RESTORING BLOOD FLOW (‘085) RUSSIA: (1) CELUTION FOR RESTORING BLOOD FLOW (‘924) SOUTH AFRICA: (1) ADRCS FOR CARDIAC (‘446) MEXICO: (1) CELUTION FOR RESTORING BLOOD FLOW (‘775) ISRAEL: (1) ADRCS FOR CARDIAC (‘354) CANADA: (1) ADRCS FOR RESTORING BLOOD FLOW(‘510) JAPAN: (1) CELUTION FOR RESTORING BLOOD FLOW(‘787) US: (3) CELUTION FOR BONE (‘043) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS (‘716) ADRCS FOR WOUND HEALING (‘580) EUROPE: (2) CELUTION FOR ACUTE TUBULAR NECROSIS (‘834) ADRCS FOR WOUND HEALING (‘833) JAPAN: (3) ADRCS FOR WOUND HEALING (‘699) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS (‘119) CELUTION FOR PERIPHERAL VASCULAR DISEASE (‘511) INDIA: (1) ADRCS FOR WOUND HEALING (‘580) US: (6) CELUTION DEVICE (‘484) CELUTION DEVICE PLUS ADDITIVES (‘420) STEMSOURCE DEVICE (‘115) CELUTION DEVICE PLUS SENSORS FOR CLINICALLY SAFE OUTPUT (‘670) BEDSIDE COMPREHENSIVE DEVICE (‘059) CELUTION DEVICE CD31 POSITIVE CELLS (‘276) JAPAN: (2) CELUTION DEVICE (‘952) CELUTION FOR CLINICALLY SAFE OUTPUT (‘556) KOREA: (3) CELUTION DEVICE (‘995) STEMSOURCE DEVICE (‘812) CELUTION DEVICE (‘139) INDIA: (1) CELUTION DEVICE (‘706) AUSTRALIA: (2) CELUTION DEVICE (‘135) STEMSOURCE DEVICE (‘901) CHINA: (1) CELUTION DEVICE (‘689) US: (1) CELUTION & FUTURE GENERATIONS (‘075) CHINA: (1) CELUTION & FUTURE GENERATIONS (‘241) INDIA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘529) AUSTRALIA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘937) SINGAPORE: (1) CELUTION & FUTURE GENERATIONS (‘683) ISRAEL: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘800) MEXICO: (1) CELUTION & FUTURE GENERATIONS (‘348) KOREA: (1) CELUTION WITH CENTRIFUGE OR FILTER (‘305) US: (6) CELUTION FOR MIXING ADRCS PLUS FAT (‘488) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS (‘684) ADRCS PLUS FAT PLUS ADDITIVES (‘795) ADRCS PLUS FAT (‘672) ADRCS PLUS FAT COMPOSITION (‘121) CURRENT CELUTION DEVICE + FAT (‘947) JAPAN: (1) CELUTION AND NEXT GEN DEVICES FOR MIXING ADRCS PLUS FAT (‘041) KOREA: (3) ADRCS PLUS FAT (‘454) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS (‘508) ADRCS PLUS FAT METHOD (‘666) EUROPE: (2) ADRCS FOR CARDIAC (‘382) OPPOSED DEVICE FOR RESTORING BLOOD FLOW (‘575) OPPOSED AUSTRALIA: (1) ADRCS FOR CARDIAC (‘858) SINGAPORE: (1) ADRCS FOR RESTORING BLOOD FLOW(‘309) CHINA: (1) ADRCS FOR RESTORING BLOOD FLOW (‘104) HONG KONG: (1) ADRCS FOR RESTORING BLOOD FLOW (‘085) RUSSIA: (1) CELUTION FOR RESTORING BLOOD FLOW (‘924) SOUTH AFRICA: (1) ADRCS FOR CARDIAC (‘446) MEXICO: (1) CELUTION FOR RESTORING BLOOD FLOW (‘775) ISRAEL: (1) ADRCS FOR CARDIAC (‘354) CANADA: (1) ADRCS FOR RESTORING BLOOD FLOW(‘510) JAPAN: (1) CELUTION FOR RESTORING BLOOD FLOW(‘787) US: (3) CELUTION FOR BONE (‘043) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS (‘716) ADRCS FOR WOUND HEALING (‘580) EUROPE: (2) CELUTION FOR ACUTE TUBULAR NECROSIS (‘834) ADRCS FOR WOUND HEALING (‘833) JAPAN: (3) ADRCS FOR WOUND HEALING (‘699) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS (‘119) CELUTION FOR PERIPHERAL VASCULAR DISEASE (‘511) INDIA: (1) ADRCS FOR WOUND HEALING (‘580)
  14. 14. Key MilestonesKey Milestones  Australia, New Zealand Approvals • Complete enrollment in the ATHENA trial • Report six month outcomes from the ATHENA trial • Achieve proof-of-concept milestones in the BARDA contract and qualify Cytori for up to $56 million in additional development funding • Initiate enrollment in the higher dose ATHENA II trial • Complete enrollment in the ATHENA II trial • Achieve product & contract revenue objective • Strengthen the company’s financial position  Australia, New Zealand Approvals • Complete enrollment in the ATHENA trial • Report six month outcomes from the ATHENA trial • Achieve proof-of-concept milestones in the BARDA contract and qualify Cytori for up to $56 million in additional development funding • Initiate enrollment in the higher dose ATHENA II trial • Complete enrollment in the ATHENA II trial • Achieve product & contract revenue objective • Strengthen the company’s financial position 14
  15. 15. Key MilestonesKey Milestones • Expand clinical development pipeline via investigator initiated studies • Additional Japan MHLW-CTG Approved Studies • Japan Legislative / Regulatory changes to Fast Track products • Initiate multiple new patient registries as part of commercial strategy • Publish the 18-month outcomes from the PRECISE European chronic ischemic heart failure trial • Continue to expand Intellectual Property portfolio • Expand clinical development pipeline via investigator initiated studies • Additional Japan MHLW-CTG Approved Studies • Japan Legislative / Regulatory changes to Fast Track products • Initiate multiple new patient registries as part of commercial strategy • Publish the 18-month outcomes from the PRECISE European chronic ischemic heart failure trial • Continue to expand Intellectual Property portfolio 15
  16. 16. Personalized Cell TherapyPersonalized Cell TherapyC Y T O R IC Y T O R I T H A N K Y O U !

×